Skip to main content

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes c, Andreu Vilaseca Jolonch, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 233750
Reference: PI24/01088
Duration: 01/01/2025 - 31/12/2027

Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias de remielinización en pacientes con esclerosis múltiple

IP: Andres Miguez Gonzalez
Collaborators: Gloria López Comellas, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140000
Reference: PI24/01117
Duration: 01/01/2025 - 31/12/2027

Human induced pluripotent stem cell-based chimeric mice to study astrocyte pathology and neuroprotective strategies in multiple sclerosis patients

IP: Manuel Comabella Lopez
Collaborators: Andres Miguez Gonzalez, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 286770
Reference: PI21/01611
Duration: 01/01/2022 - 30/06/2025

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...
Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Arnau Cortés Nuet

Arnau Cortés Nuet

Tècnic de recerca
Technological Infrastructure Unit
Digital Transformation Directorate
Read more
Manuel Jesus Iglesias Cabezas

Manuel Jesus Iglesias Cabezas

Predoctoral researcher
Microbiology
Read more
Maria Antonia Perello Barcelo

Maria Antonia Perello Barcelo

Predoctoral researcher
Maternal and Fetal Medicine
Read more
Carmen Rodriguez Fernandez

Carmen Rodriguez Fernandez

Research technician
Ophtalmology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.